spironolactone

(redirected from Aldactone)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

spironolactone

[′spī·rə·nō′lak‚tōn]
(pharmacology)
C24H32O4S A steroid having a lactone ring attached at carbon-17; used as a diuretic.
Mentioned in ?
References in periodicals archive ?
The side-effects of aldactone include anti-androgenic effects through the antagonism of dihydrotestosterone at its binding site.
The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators.
Remembering that Aldactone blocked the action of aldosterone, Weber and his colleagues found they could use it to prevent formation of connective tissue in the hearts of their experimental animals.
This patient had chronic renal failure, was taking prescription drugs (Zestril is an ACE inhibitor, Toprol is a beta-blocker, and Aldactone inhibits aldosterone), ate a large volume of food that contained potassium (bananas), and had diabetes.
The Randomized Aldactone Evaluation Study (RALES) demonstrated a survival advantage with the aldosterone antagonist spironolactone (Aldactone) plus standard therapy in moderate to severe heart failure patients, while the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) did so in the post-MI/heart failure setting.
Inspra's selectivity means that it lacks some of the side effects of Aldactone (spironolactone) such as gynecomastia.
5 mg QD (Mykrox) Polythiazide Renese 2-4 mg QD Spironolactone (*) Aldactone 50-100 mg/day in single or divided doses Torsemide Demadex 5 mg QD Trichlormethiazide (*) Metahydrin, 2-4 mg QD Naqua, Diurese Classification/Drug Usual Dosage Range Amiloride (*) 5-20 mg QD Benzthiazide (*) 50-150 mg/day in divided doses Chlorothiazide (*) 500-2,000 mg/day in single or divided doses Chlorthalidone (*) 25-100 mg QD Furosemide (*) 40 mg BID Hydrochlorothiazide (*) 25-100 mg QD Hydrochlorothiazide (*) 50-200 mg/day (divide doses >100 mg/day) Indapamide (*) 1.
The Randomized Aldactone Evaluation Study has already shown that the nonselective aldosterone receptor antagonist spironolactone was effective in reducing mortality in severe heart failure.
The mandate for aggressive development of SARAs was provided by the results of the Randomized Aldactone Evaluation Study (RALES), which showed that spironolactone markedly improved survival in patients who had congestive heart failure and were already on standard multidrug therapy.